Assessment of the associations between three VEGF polymorphisms and risk of prostate cancer.
Vascular endothelial growth factor (VEGF) plays a crucial role in the regulation of angiogenesis and is involved in the development and metastasis of common cancers. There were several case-controls studies published to assess the associations of VEGF polymorphisms with risk of prostate cancer, but the findings were inconsistent. We performed a meta-analysis to provide a comprehensive assessment of the associations of three VEGF polymorphisms with risk of prostate cancer. The pooled odds ratio (OR) with 95% confidence interval (95% CI) was calculated to assess the associations. Eleven individual case-control studies with a total of 5,209 cases of prostate cancer and 5,233 controls were finally included into our meta-analysis. Overall, VEGF rs833061 polymorphism was not associated with risk of prostate cancer (T versus C, OR = 1.14, 95% CI 0.91-1.44, P = 0.26; TT versus CC, OR = 1.09, 95% CI 0.67-1.76, P = 0.74; TT versus OR = 1.46, 95% CI 0.67-3.18, P = 0.34; TT/CT versus CC, OR = 1.08, 95% CI 0.82-1.43, P = 0.59). VEGF rs3025039 polymorphism was also not associated with risk of prostate cancer (T versus C, OR = 1.03, 95% CI 0.91-1.16, P = 0.66; TT versus CC, OR = 1.82 95% CI 0.16-20.53, P = 0.63; TT versus CC/CT, OR = 2.00, 95% CI 0.18-22.41, P = 0.57; TT/CT versus CC, OR = 0.72, 95% CI 0.38-1.36, P = 0.31). VEGF rs2010963 polymorphism was not associated with risk of prostate cancer under three models (C versus G, OR = 1.17, 95% CI 0.92-1.48, P = 0.20; CC versus GG, OR = 2.28, 95% CI 0.90-5.75, P = 0.08; CC versus GG/GC, OR = 1.57, 95% CI 0.67-3.68, P = 0.30). In conclusison, current data suggest that those three VEGF polymorphisms are not obviously associated with risk of prostate cancer.